Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Karyopharm Therapeutics (KPTI) Interest & Investment Income (2016 - 2025)

Karyopharm Therapeutics' Interest & Investment Income history spans 13 years, with the latest figure at $607000.0 for Q4 2025.

  • For Q4 2025, Interest & Investment Income fell 59.04% year-over-year to $607000.0; the TTM value through Dec 2025 reached $2.8 million, down 62.53%, while the annual FY2025 figure was $2.8 million, 62.53% down from the prior year.
  • Interest & Investment Income reached $607000.0 in Q4 2025 per KPTI's latest filing, up from $553000.0 in the prior quarter.
  • In the past five years, Interest & Investment Income ranged from a high of $2.8 million in Q1 2023 to a low of $55000.0 in Q4 2021.
  • Average Interest & Investment Income over 5 years is $1.2 million, with a median of $829000.0 recorded in 2022.
  • Peak YoY movement for Interest & Investment Income: plummeted 86.11% in 2021, then soared 3750.0% in 2023.
  • A 5-year view of Interest & Investment Income shows it stood at $55000.0 in 2021, then soared by 2325.45% to $1.3 million in 2022, then surged by 88.91% to $2.5 million in 2023, then plummeted by 41.19% to $1.5 million in 2024, then tumbled by 59.04% to $607000.0 in 2025.
  • Per Business Quant, the three most recent readings for KPTI's Interest & Investment Income are $607000.0 (Q4 2025), $553000.0 (Q3 2025), and $613000.0 (Q2 2025).